REGISTER
Allist’s Furmonertinib Approved for a New Indication
Allist’s third-generation EGFR-TKI furmonertinib has been approved in China for previously treated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after or during platinum-based chemotherapy, becoming the drug’s third approved indication in the country.

On February 6, the NMPA website showed that a new indication had been approved for Allist’s furmonertinib mesylate tablets, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations confirmed by testing, whose disease progressed during or after platinum-based chemotherapy or who were intolerant to platinum-based chemotherapy. This indication had previously been included in priority review by the CDE.

Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI). It had already been approved in China for two indications, both included in the National Reimbursement Drug List. This is the third approved indication for the drug in China.

In March 2021, it was approved for adult patients with locally advanced or metastatic NSCLC harboring EGFR T790M-positive mutations whose disease had progressed during or after prior EGFR TKI treatment.

In June 2022, it was approved as first-line treatment for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations.

At the 2025 ESMO Congress, Allist presented for the first time, in an oral report, results from the Phase II FURMO-003 study of furmonertinib in previously treated patients with advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.

The study enrolled 71 patients with a median age of 57 years. Most had a baseline ECOG performance status score of 1, and all had received platinum-based chemotherapy. In addition, 60.6% had received targeted therapies such as anlotinib or bevacizumab, and 31.0% had received immunotherapy. The vast majority of patients had stage IVA or IVB disease.

Results showed a best overall response rate (BOR) of 51.4% and a confirmed objective response rate (ORR) of 44.3% as assessed by an independent review committee (IRC). Excluding the five patients without measurable disease at baseline by IRC assessment, the confirmed ORR was 47.0%, meaning nearly half of patients achieved marked tumor shrinkage. According to IRC assessment under RECIST 1.1, 2 of 8 patients with measurable baseline central nervous system disease achieved CNS partial response.

Most patients experienced partial response or stable disease; only 6 progressed and 1 was not evaluable. The disease control rate was 90.0%, median duration of response was 8.3 months, and the longest duration of response exceeded 24 months, showing strong tumor suppression. Median progression-free survival was 8.3 months, and median overall survival observed so far was 21.2 months.

Most responses occurred at the first tumor assessment, with a median time to first response of 1.4 months, consistent with furmonertinib’s rapid tumor-shrinkage profile seen in earlier studies. Furmonertinib showed clear tumor inhibition regardless of whether the insertion mutation was located in the near loop, far loop, or helical region.

In addition, the overall safety profile of furmonertinib was consistent with previous clinical studies, and no new or unexpected safety signals were identified.

It is also worth noting that the global Phase III FURVENT trial of furmonertinib as first-line treatment for EGFR exon 20 insertion NSCLC completed enrollment in 2025 and is currently in the follow-up stage.

0
0
Loading